Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Recruiting Phase 2 Interventional

Evaluation of YB-101 for Safety, Tolerability, Pharmacokinetics, and Efficacy in Graves' Disease

ClinicalTrials.gov ID: NCT07682896

Public ClinicalTrials.gov record NCT07682896. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 5, 2026, 11:22 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Blinded, Placebo-Controlled, Two-Part, Phase 2 Study to Assess Safety, Tolerability, Pharmacokinetics, and Efficacy of YB-101 in Participants With Graves' Disease

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study is being conducted to look at the effect YB-101 has on thyroid function. This study will also evaluate how safe and well tolerated YB-101 is and how it is distributed through the body. The study consists of a part 1, blinded treatment period, and a part 2 double-blinded treatment period. Participants will receive YB-101 or Placebo subcutaneously. Participants who participate in Part 1 can not participate in Part 2. Participants will complete 34-39 in-clinic visits in Part 1 or Part 2 over an approximate 40 week period.

Study identification

NCT ID
NCT07682896
Recruitment status
Recruiting
Study type
Interventional
Phase
Phase 2
Lead sponsor
Yarrow Bioscience, Inc.
Industry
Enrollment
232 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jun 9, 2026
Primary completion
Nov 30, 2027
Completion
Aug 31, 2029
Last update posted
Sep 3, 2026

2026 – 2029

United States locations

U.S. sites
28
U.S. states
11
U.S. cities
28
Facility City State ZIP Site status
Site 112 Gilbert Arizona 85297 Recruiting
Site 130 Phoenix Arizona 85006 Not yet recruiting
Clinical Research Site Tucson Arizona 85710 Not yet recruiting
Site 121 La Mesa California 91942 Recruiting
Site 103 Sacramento California 95817 Not yet recruiting
Site 111 San Francisco California 94143 Not yet recruiting
Site 105 Torrance California 90502 Not yet recruiting
Site 109 Miami Lakes Florida 33016 Recruiting
Site 115 Palm Harbor Florida 34684 Recruiting
Site 123 Sarasota Florida 34239 Not yet recruiting
Site 118 Macon Georgia 31210 Recruiting
Site 122 Bowling Green Kentucky 42103 Recruiting
Site 126 Flint Michigan 48532 Recruiting
Site 107 Livonia Michigan 48152 Recruiting
Site 108 Omaha Nebraska 68198 Not yet recruiting
Site 129 Niagara Falls New York 14304 Recruiting
Site 120 Orchard Park New York 14127 Recruiting
Clinical Research Site Raleigh North Carolina 27612 Not yet recruiting
Site 124 Sayre Pennsylvania 18840 Not yet recruiting
Site 100 Amarillo Texas 79124 Recruiting
Site 117 Conroe Texas 77384 Recruiting
Clinical Research Site Dallas Texas 75246 Not yet recruiting
Site 128 Edinburg Texas 78539 Recruiting
Site 127 El Paso Texas 79935 Not yet recruiting
Site 106 Fort Worth Texas 76132 Recruiting
Site 110 Houston Texas 77095 Recruiting
Site 101 Humble Texas 77346 Recruiting
Site 116 San Antonio Texas 78233 Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 2 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT07682896, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Sep 3, 2026 · Synced Sep 5, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT07682896 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →